RxDoctor Payments Data

Jason Weingart, MD

Cardiovascular Disease · Lancaster, OHNPI 1114188273

Payments from drug & device makers

$2,505in general payments, 2019–2025

Across 50 payments — averaging $50.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$691
  • Cardiovascular Systems Inc.$268
  • Abiomed$134
  • Edwards Lifesciences$130
  • AstraZeneca$68
  • plus $213 from 6 others

What the payments were for

  • Travel & lodging$1,33653%
  • Food & beverage$1,16947%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,505 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$122,504
Medicare patients
836
Services billed
1,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$226,464
XareltoRivaroxaban71$66,267
Repatha SureclickEvolocumab41$47,054
EntrestoSacubitril/Valsartan26$30,826
BrilintaTicagrelor20$14,421
Atorvastatin Calcium423$5,046
Metoprolol Succinate280$4,591
Ranolazine ErRanolazine21$3,465
Prasugrel Hcl60$3,300
ClopidogrelClopidogrel Bisulfate250$3,050
Carvedilol258$2,461
Diltiazem 24hr Er (Cd)Diltiazem Hcl51$2,336
Isosorbide Mononitrate ErIsosorbide Mononitrate118$2,005
Rosuvastatin Calcium106$1,909
Nifedipine ErNifedipine46$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$226,464222 claims
Johnson & JohnsonXarelto$51$66,26771 claims
NovartisEntresto$33$30,82626 claims
AstraZenecaBrilinta$68$14,42120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →